Regeneron Pharmaceuticals - About the company
Regeneron Pharmaceuticals is a public company based in Tarrytown (United States), founded in 1988 by Leonard Schleifer and George Yancopoulos. It operates as a Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others. Regeneron Pharmaceuticals has raised an undisclosed amount in funding. The company has 1279 active competitors, including 74 funded and 156 that have exited. Its top competitors include companies like AbbVie, Amgen and Gilead.
Company Details
Regeneron Pharmaceuticals is a developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others. It is developing antibody products include ARCALYST (rilonacept), an anti-inflammatory agent, EYLEA (aflibercept) Injection, also known as VEGF Trap-Eye, and Intravitreal Aflibercept injection. It has also developed PRALUENT (alirocumab) Injection that is a PCSK9 inhibitor. Its Phase 3 pipeline includes antibodies for the treatment of rheumatoid arthritis, topic dermatitis in adults, asthma, respiratory syncytial virus, chronic lower back pain, and others. Its Phase 2 pipeline drugs are for the treatment of Atopic dermatitis in children, nasal polyps, eosinophilic esophagitis, non-infectious uveitis, skeletal muscle disorders. In 2022, the company recorded annual revenues of $12.17B and a net profit of $4.33B.
- Website
- www.regeneron.com/
- Social
- Registered Address
- Tarrytown, New York
Key Metrics
Founded Year
1988
Location
Tarrytown, United States
Stage
Public
Latest Funding Round
Investors
Ranked
9th among 1279 active competitors
Annual Revenue
$14.3B as on Dec 31, 2025
Employee Count
16,672 as on Mar 31, 2026
Exit Details
Public
Legal entities associated with Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is associated with 5 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
REGENERON INDIA PRIVATE LIMITED CIN: U72900KA2022FTC160799 , India, Active | May 04, 2022 | $6.71M (As on Mar 31, 2025) | - | |
Regeneron Pharmaceuticals CIN: - , Belgium, Active | - | - | - | |
REGENERON PHARMACEUTICALS INC CIN: 872589 , United States, Active | Oct 03, 2011 | $14.3B (As on Dec 31, 2025) | - | - |
Regeneron Pharmaceuticals, Inc. CIN: 133444607 , United States, Active | Dec 26, 999 | $1.4B (As on Dec 31, 2024) | 11960 (As on Dec 31, 2024) | - |
Regeneron Pharmaceuticals, Inc. CIN: 001t000000WndtbAAB , United States, Active | Nov 21, 2011 | - | - | - |
Regeneron Pharmaceuticals's IPO details
Regeneron Pharmaceuticals got listed on Apr 05, 1991.
Click here to take a look at Regeneron Pharmaceuticals's IPO in detail
Sign up to download Regeneron Pharmaceuticals' company profile
Regeneron Pharmaceuticals's funding and investors
Regeneron Pharmaceuticals has raised funding over 2 rounds. Its first funding round was on Sep 12, 2007. Its latest funding round was a Grant (prize money) round on Aug 28, 2010 for $*****. 1 investor participated in its latest round. Regeneron Pharmaceuticals has 9 institutional investors.
Here is the list of recent funding rounds of Regeneron Pharmaceuticals:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Aug 28, 2010 | 2994775 | Grant (prize money) | 2456545 | 6968585 | 9506804 | 6503354 |
Sep 12, 2007 | 7997014 | Grant (prize money) | 6264916 | 1614882 | 8094141 |
Access funding benchmarks and valuations. Sign up today!View details of Regeneron Pharmaceuticals's funding rounds and investors
Regeneron Pharmaceuticals' founders and board of directors
Founder? Claim ProfileThe founders of Regeneron Pharmaceuticals are Leonard Schleifer and George Yancopoulos. Leonard Schleifer is the CEO of Regeneron Pharmaceuticals.
Here are the details of Regeneron Pharmaceuticals' key team members:
- Leonard Schleifer: Co-Founder & CEO of Regeneron Pharmaceuticals. Contact Info: 1 email address
- George Yancopoulos: President, Chief Scientific Office & co-Founder of Regeneron Pharmaceuticals.
View details of Regeneron Pharmaceuticals's Founder profiles and Board Members
Regeneron Pharmaceuticals' employee count trend
Regeneron Pharmaceuticals has 16,672 employees as of Mar 26. Here is Regeneron Pharmaceuticals's employee count trend over the years:
Uncover Regeneron Pharmaceuticals' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Regeneron Pharmaceuticals's Competitors and alternates
Top competitors of Regeneron Pharmaceuticals include AbbVie, Amgen and Gilead. Here is the list of Top 10 competitors of Regeneron Pharmaceuticals, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | AbbVie 2012, Chicago (United States), Public | Research-based biopharmaceutical company | $14.7B | 81/100 | |
2nd | Amgen 1980, Thousand Oaks (United States), Public | Developer of pharmaceutical products for treating multiple diseases | - | 81/100 | |
3rd | Gilead 1987, Foster City (United States), Acquired | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | - | 80/100 | |
4th | Lilly 1876, Indianapolis (United States), Public | Developer of traditional pharmaceutical medicines | - | 79/100 | |
5th |  Johnson & Johnson 1886, New Brunswick (United States), Public | Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products | - | 76/100 | |
6th | Juno Therapeutics 2013, Seattle (United States), Acquired | Global biopharmaceutical company discovering, developing, and delivering innovative medicines | $317M | 74/100 | |
7th |  Pfizer 1849, New York City (United States), Public | Provider of pharmaceutical products for multiple disease treatments | - | 72/100 | |
8th |  Roivant Sciences 2014, New York City (United States), Public | Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases | $1.3B | 72/100 | |
9th |  Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public | Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others | - | 71/100 | |
10th | Novartis 1996, Basel (Switzerland), Public | R&D focused on manufacturing of drugs for multiple therapeutic areas | - | 70/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Regeneron Pharmaceuticals's competitors? Click here to see the top ones
Regeneron Pharmaceuticals's Investments and acquisitions
Regeneron Pharmaceuticals has made 7 investments in companies including Truveta and Enlaza. Regeneron Pharmaceuticals has also acquired 4 companies including Oxular and Decibel Therapeutics.Here is the list of investments & acquisitions:
Filter this list
Filter this listDate of Investment/Acquisition | Type | Company Name | Founded Year | Location |
|---|---|---|---|---|
Jan 13, 2025 | Investments | 2020 | Seattle (United States) | |
Jan 02, 2025 | Acquisition | 2014 | Oxford (United Kingdom) | |
Apr 30, 2024 | Investments | 2020 | La Jolla (United States) |
Want to know more about where corporates are investing? Sign up today!See all investments and acquisitions by Regeneron Pharmaceuticals
News related to Regeneron Pharmaceuticals
Filter this listMedia has covered Regeneron Pharmaceuticals for a total of 181 events in the last 1 year, 102 of them have been about company updates and 9 about partnerships.
•
PKO Investment Management Cuts Regeneron Pharmaceuticals Stake by 56.7%MarketBeat•May 03, 2026•PKO, Regeneron Pharmaceuticals
•
•
•
Regeneron Flags FDA Delays For Eylea HD Prefilled SyringeBenzinga•Apr 29, 2026•Regeneron Pharmaceuticals
•
Regeneron Announces Agreement with U.S. Government to Help Lower Drug CostsGlobeNewswire•Apr 24, 2026•Regeneron Pharmaceuticals
•
Sanofi and Regeneron's Dupixent Approved in the US for Young Children with CSUWebDisclosure•Apr 23, 2026•Regeneron Pharmaceuticals
•
•
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Regeneron Pharmaceuticals
Explore our recently published companies
- DOBI - Suhr based, 1963 founded, Public company
- Stop Go Networks - United Kingdom based, 2010 founded, Public company
- Odd Job Nation - United States based, Public company
- The College Voice - New London based, 1916 founded, Public company
- paleoent - San Diego based, 2006 founded, Public company
- Process Governance Consulting Group - Orlando based, 2009 founded, Public company
